Liquidia Technologies has added an additional investor, PPD, Inc., to its Series C financing
RESEARCH TRIANGLE PARK, N.C., April 20, 2010 --(EON: Enhanced Online News)-- Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million. The initial Series C closing was announced in January 2010.
Liquidia Technologies, a privately held biopharmaceutical company developing particle‐based vaccines and therapeutics, today announced it has completed a $20 million round of Series C financing. Canaan Partners led the Series C round, which also included Pappas Ventures and Morningside Venture Investments Limited as new investors. Previous investors, including New Enterprise Associates and Firelake Capital, also participated in the financing round. The funds will be used to accelerate Liquidia’s lead vaccine candidate through initial clinical evaluation and expand development of particle‐based solutions for siRNA delivery and inhaled therapeutics.
Research Triangle Park, NC – April 20, 2010 – Liquidia Technologies, a privately held biopharmaceutical company developing particle‐based vaccines and therapeutics, today announced it has completed a $20 million round of Series C financing. Canaan Partners led the Series C round, which also included Pappas Ventures and Morningside Venture Investments Limited as new investors. Previous investors, including New Enterprise Associates and Firelake Capital, also participated in the financing round. The funds will be used to accelerate Liquidia’s lead vaccine candidate through initial clinical evaluation and expand development of particle‐based solutions for siRNA delivery and inhaled therapeutics.
